Skip to main content
SpringerLink
Log in

Management of Amyotrophic Lateral Sclerosis

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the motor neurons, in both the spinal cord and medulla (lower motor neurons) and cerebral cortex (upper motor neurons). Even though ALS remains fatal, several advances have been made during the last decade in improving the consequences of motor dysfunction, quality of life and survival time of patients. Treatment of ALS cannot be restricted to riluzole, the only molecule that has been proved to modify the evolution of the disease. Symptomatic treatments have an important role in controlling the major consequences of the disease, such as pain, sleep disorders, spasticity, hypersialhorroea, emotional lability, depression and digestive disorders (constipation and reflux). All these symptoms need to be recognized and their possible causes identified in order to provide the most appropriate management of patients with ALS.

However, an advance in the daily care of patients is the identification of two important phenomena that occur during the evolution of the disease: swallowing difficulties and the occurrence of diaphragmatic dysfunction. For both, specific medical interventions have been developed to allow correction of the consequences (i.e. weight loss and respiratory insufficiency). Although no controlled trials have been performed, observational studies suggest that gastrostomy and non-invasive ventilation may improve at least quality of life and survival.

All of these various approaches, pharmaceutical and non-pharmaceutical therapies, are prescribed according to individual symptoms and require the involvement of a large range of health professionals. This multidisciplinary approach in ALS clinics is considered to be one of the more important factors impacting on survival rate and appears to be the gold standard of medical care of ALS patients.

Important findings have been made in understanding the nature of the degenerative process that affects the motor neurons. All these data have allowed new therapeutic molecules to be tested alone or in combination with riluzole. Despite the negative results obtained until now, we hope to demonstrate very soon a greater improvement in therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–700

    Article  PubMed  CAS  Google Scholar 

  2. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–19

    Article  PubMed  Google Scholar 

  3. Andersen PM, Borasio GD, Dengler R, et al., on behalf of the EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005 Dec; 12(12): 921–38

    Article  PubMed  CAS  Google Scholar 

  4. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis: 2. Familial aggregations indicative of dominant inheritance part II. Neurology 1955; 5: 249–68

    Article  PubMed  CAS  Google Scholar 

  5. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031–41

    Article  PubMed  CAS  Google Scholar 

  6. Brooks BR, Miller RG, Swash M, et al. El Escortal revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler 2000; 1: 293–9

    Article  CAS  Google Scholar 

  7. Pradat PF, Bruneteau G. Clinical characteristics of ALS subsets. Rev Neurol 2006; 162: 4S29–33

    PubMed  Google Scholar 

  8. Ringholz GM, Greene SR. The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Curr Neurol Neurosci Rep 2006; 5: 387–92

    Article  Google Scholar 

  9. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130–3

    Article  PubMed  CAS  Google Scholar 

  10. Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: a population based study. Arch Neurol 2000; 57: 109–13

    Article  PubMed  CAS  Google Scholar 

  11. Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958–64

    Article  PubMed  CAS  Google Scholar 

  12. Isaacs JD, Dean AF, Shaw CE, et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry 2007; 78: 750–3

    Article  PubMed  Google Scholar 

  13. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003 Dec; 74 Suppl. 4: iv32–47

    Article  PubMed  Google Scholar 

  14. La Spada A, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77–9

    Article  PubMed  Google Scholar 

  15. Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77: 948–50

    Article  PubMed  CAS  Google Scholar 

  16. Mizuta I, Ohta M, Ohta K, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117–20

    Article  PubMed  CAS  Google Scholar 

  17. Beltran-Parrazal L, Charles A. Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels. Br J Pharmacol 2003; 140: 881–8

    Article  PubMed  CAS  Google Scholar 

  18. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/riluzole Study Group. N Eng J Med 1994; 330: 585–91

    Article  CAS  Google Scholar 

  19. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 348: 336–7

    Google Scholar 

  20. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; (1): CD001447

  21. Francis K, Bach JR, DeLisa JA. Evaluation and rehabilitation of patients with adult motor neuron disease. Arch Phys Med Rehabil 1999; 80: 951–63

    Article  PubMed  CAS  Google Scholar 

  22. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. J Neurol 1997; 244 Suppl. 4: S2–10

    Article  PubMed  Google Scholar 

  23. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005; 22: 55–9

    Article  PubMed  Google Scholar 

  24. Miller RG, Anderson Jr FA, Bradley WG, et al. The ALS patient care database: goals, design and early results. ALS C.AR.E. Study Group. Neurology 2000; 54: 53–7

    CAS  Google Scholar 

  25. Kurt A, Nijboer F, Matuz T, et al. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs 2007; 21: 279–91

    Article  PubMed  Google Scholar 

  26. Vojtech H, Kabrnova K, Aldhoon B, et al. Serotonin and nore-pinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252–69

    Article  Google Scholar 

  27. Talmi YP, Finkelstein Y, Zohar Y. Reduction on salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS [letter]. Head Neck 1989; 11: 565

    Article  PubMed  CAS  Google Scholar 

  28. Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006; 34: 235–7

    Article  PubMed  CAS  Google Scholar 

  29. Borasio G, Voltz R. Palliative care in amyotrophic lateral sclerosis. J Neurol 1997; 244: S11–7

    Article  PubMed  Google Scholar 

  30. Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis [letter]. Neurology 2002; 58: 1308

    Article  PubMed  Google Scholar 

  31. Cintas P. Drug therapy for symptomatic relief in ALS. Rev Neurol 2006; 162: 4S235–43

    PubMed  Google Scholar 

  32. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 Suppl.: 43–4

    Article  PubMed  Google Scholar 

  33. Sancho J, Servern E, Diaz J, et al. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125: 1400–5

    Article  PubMed  Google Scholar 

  34. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1995; 48: 838–40

    Article  Google Scholar 

  35. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999; 52: 1434–40

    Article  PubMed  CAS  Google Scholar 

  36. Stefanovska A, Rebersek S, Bajd T. Effect of electrical stimulation on spasticity. Crit Rev Phys Rehabil Med 1991; 3: 59–99

    Google Scholar 

  37. Ukada F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984; 41: 1095–6

    Article  Google Scholar 

  38. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextrometorphan/quinidine: a randomized trial. Neurology 2004; 63: 1364–70

    Article  PubMed  CAS  Google Scholar 

  39. Tariq SH. Constipation in long-term care. J Am Med Dir Assoc 2007; 8: 209–18

    Article  PubMed  Google Scholar 

  40. Forshew DA, Bromberg MB. A survey of clinician’s practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler 2003; 4: 258–63

    Article  Google Scholar 

  41. Bortolotti M. Laryngospasm and reflex central apnea caused by aspiration of refluxed gastric content in adults. Gut 1989; 30: 233–8

    Article  PubMed  CAS  Google Scholar 

  42. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007; 22: 213–9

    Article  PubMed  Google Scholar 

  43. Walters AS, Ondo WG, Dreykluft T, et al. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19: 1414–23

    Article  PubMed  Google Scholar 

  44. Ono S. The skin in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000; 1: 191–9

    Article  CAS  Google Scholar 

  45. Watanabe S, Yamada K, Ono S, et al. Skin changes in patients with amyotrophic lateral sclerosis: light and electro microscopic observations. J Am Acad Dermatol 1987; 17: 1006–12

    Article  PubMed  CAS  Google Scholar 

  46. Sasaki S, Tsutsumi Y, Tamane K, et al. Sporadic amyotrophic lateral sclerosis with extensive neurological involvement. Acta Neuropathol 1992; 84: 211–5

    Article  PubMed  CAS  Google Scholar 

  47. Qureshi M, Cudkowicz ME, Zhang H, et al. Increased incidence of deep venous thrombosis in ALS. Neurology 2007; 68: 76–7

    Article  PubMed  Google Scholar 

  48. Kimura F, Ishida S, Furutama D, et al. Wheelchair economy class syndrome in amyotrophic lateral sclerosis [letter]. Neuromuscul Disord 2006; 16: 207

    Article  Google Scholar 

  49. Norris Jr FH, U KS, Sachais B, et al. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol 1979; 36: 715–6

    Article  PubMed  Google Scholar 

  50. Ashworth NI, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease (Review). Cochrane Database Syst Rev 2006; (1): CD004156

  51. Marquandt G, Lorenz R. Intrathecal baclofen for intractable spasticity in ALS. J Neurol 1999; 256: 619–20

    Article  Google Scholar 

  52. Marquandt G, Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 275–6

    Article  Google Scholar 

  53. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry 2003; 74: 1258–61

    Article  PubMed  CAS  Google Scholar 

  54. Desnuelle C, Bruno M, Soriani MH, et al. What physical therapy techniques can be used to improve airway freedom. Rev Neurol 2006; 162: 4S244–52

    PubMed  Google Scholar 

  55. Johnson CR. Aquatic therapy for an ALS patient. Am J Occup Ther 1988; 42: 115–20

    Article  PubMed  CAS  Google Scholar 

  56. Howard RS, Orrell RW. Management of motor neuron disease. Postgrad Med 2002; 78: 736–41

    Article  CAS  Google Scholar 

  57. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler 2004; 5: 67–71

    Article  CAS  Google Scholar 

  58. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000–13

    Article  PubMed  CAS  Google Scholar 

  59. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 913–25

    Article  PubMed  Google Scholar 

  60. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidenced-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1999; 52: 1311–23

    CAS  Google Scholar 

  61. Polkey MI, Lyall RA, Green M, et al. Expiratory muscle function in amyotrophic lateral sclerosis. Am J Crit Care Med 1998; 158: 734–41

    CAS  Google Scholar 

  62. Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax 1995; 50: 1131–5

    Article  PubMed  CAS  Google Scholar 

  63. Morgan RK, McNally S, Alexander M, et al. Use of SNIP nasalinspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Resp Crit Care Med 2005; 171: 269–74

    Article  PubMed  Google Scholar 

  64. Perez T. Amyotrophic lateral sclerosis (ALS): evaluation of respiratory function. Rev Neurol 2006; 162: 4S188–94

    PubMed  Google Scholar 

  65. Pinet C. What is the role of life support systems? Rev Neurol 2006; 162: 4S266-68

    Google Scholar 

  66. Lechtzin N, Weiner CM, Clawson L, et al. Hospitalization in amyotrophic lateral sclerosis: causes, costs and outcomes. Neurology 2001; 56: 753–7

    Article  PubMed  CAS  Google Scholar 

  67. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53: 1059–63

    Article  PubMed  CAS  Google Scholar 

  68. Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005; 2: 202–7

    Article  PubMed  Google Scholar 

  69. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004–9

    Article  PubMed  CAS  Google Scholar 

  70. Boitano LJ, Jordan T, Benditt JO. Non invasive ventilation allows gastrostomie tube placement in patients with advanced ALS. Neurology 2001; 56: 413–4

    Article  PubMed  CAS  Google Scholar 

  71. Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low capacity: respiratory support and survival. Neurology 2002; 58: 485–7

    Article  PubMed  Google Scholar 

  72. Bouteloup C. What are the means of alimentary function supply and their indications? Rev Neurol 2006; 162: 4S309–19

    Article  PubMed  Google Scholar 

  73. Desport JC, Mabrouk T, Bouillet P, et al. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2005; 6: 88–93

    Article  Google Scholar 

  74. Thornton FJ, Fotheringham T, Alexander M, et al. Amyotrophic lateral sclerosis: enterai nutrition provision-endoscopic or radiologic gastrostomy? Radiology 2002; 224: 713–7

    Article  PubMed  Google Scholar 

  75. Couratier P, Desport JC, Antonini MT, et al. Review of nutritional and respiratory support in ALS. Rev Neurol 2004; 160: 243–50

    Article  PubMed  CAS  Google Scholar 

  76. Neudert C, Olivier D, Wasner M, et al. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612–6

    Article  PubMed  CAS  Google Scholar 

  77. Camu W, Khoris J, Moulard B, et al. Genetics of familial ALS and consequences for diagnosis. J Neurol Sci 1999; 165: S21–6

    Article  PubMed  Google Scholar 

  78. Hand C, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 25: 135–59

    Article  PubMed  CAS  Google Scholar 

  79. Orrell RW, Figliewicz DA. Clinical implications of the genetics of ALS and other motor neuron diseases. Neurology 2001; 57: 9–17

    Article  PubMed  CAS  Google Scholar 

  80. Mayeux V, Corcia P, Besson G, et al. N19S, a new Superoxide dismutase gene mutation in sporadic amyotrophic lateral sclerosis: no evidence for disease causation. Ann Neurol 2003; 53: 815–8

    Article  PubMed  CAS  Google Scholar 

  81. Rezania K, Yan J, Dellafave L, et al. A rare Cu/Zn Superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset, incomplete penetrance and a sensory neuropathy. Amyotroph Lateral Scler 2003; 4: 162–6

    Article  CAS  Google Scholar 

  82. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala Cu,Zn Superoxide dismutase mutation: a clinical and genealogical study of 36 patients. Brain 1996; 119: 1153–72

    Article  PubMed  Google Scholar 

  83. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in SOD in ALS. Ann Neurol 1997; 41: 210–21

    Article  PubMed  CAS  Google Scholar 

  84. Regal L, Vanopdenbosch L, Tilkin P, et al. The G93C mutation in Superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch Neurol 2006; 63: 262–7

    Article  PubMed  Google Scholar 

  85. Corcia P. Methods of the announcement of ALS diagnosis in familial forms. Rev Neurol 2006; 162: 4S122–6

    PubMed  Google Scholar 

  86. Van den Berg JP, Kalmijn S, Linderman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65: 1264–7

    Article  PubMed  Google Scholar 

  87. Nirmalananthana N, Greensmitha L. Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol 2005; 18: 712–9

    Article  Google Scholar 

  88. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60: 22–31

    Article  PubMed  CAS  Google Scholar 

  89. Gordon PH, Moore DH, Florence JM, et al. Results of the phase III randomized controlled trial of minocycline in ALS [abstract]. Neurology 2007; 68 Suppl. 1: 90

    Google Scholar 

  90. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045–53

    Article  PubMed  CAS  Google Scholar 

  91. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler 2004; 5: 107–17

    Article  CAS  Google Scholar 

  92. Mazzini L, Mareschi K, Ferrero I, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006; 28: 523–6

    Article  PubMed  Google Scholar 

  93. Lepore AC, Maragakis NJ. Targeted stem cell transplantation strategies in ALS. Neurochem Int 2007; 50: 966–75

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Fédération des maladies du système nerveux, Centre référent SLA, Pavillon Paul Castaigne, Hôpital de la Salpétrière, 47 boulevard de l’Hôpital, Paris, 75013, France

    Philippe Corcia &  Vincent Meininger

Authors
  1. Philippe Corcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent Meininger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent Meininger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corcia, P., Meininger, V. Management of Amyotrophic Lateral Sclerosis. Drugs 68, 1037–1048 (2008). https://doi.org/10.2165/00003495-200868080-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868080-00003

Keywords

Search

Navigation